Bridgewest Group, a global private investment firm focused on developing companies in life sciences, software and deep technology, has bought the sterile injectable manufacturing facility of Pfizer (Perth) Proprietary Ltd., a subsidiary of Pfizer Inc.
The current good manufacturing practices (cGMP) manufacturing facility located in Bentley, a Perth suburb in Western Australia, is a sterile injectable manufacturing facility, approved to supply drug products in over 90 countries with approvals from the FDA, TGA, EU and others. Bridgewest Group will also acquire a suite of drug products from Pfizer, which the company aims to market and expand globally.
“We are thrilled to add another center of excellence in an area that is so important to the health and well-being of others,” says Masood Tayebi, co-founder and chief executive officer of Bridgewest Group. “The team and systems in Perth are world-class, and the opportunity for growth is huge. Australia has an active and forward-thinking medical science community with outstanding universities, advanced research, and clinical trial capabilities.”